ReviewExpert opinion on drug delivery2009
New strategies to deliver anticancer drugs to brain tumors.
Review in Expert opinion on drug delivery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 211 citations in OpenAlex.
- Assessing progesterone receptor modulation in glioblastoma: fromCancer biology & therapy · 2026Article
- Engineered nanoparticles as a promising drug delivery system for glioblastoma multiforme treatment.Therapeutic delivery · 2025Review
- Navigating the brain: Harnessing endogenous cellular hitchhiking for targeting neoplastic and neuroinflammatory diseases.Asian journal of pharmaceutical sciences · 2025Review
- Advancements and challenges in brain cancer therapeutics.Exploration (Beijing, China) · 2024Review
- Discovery of key molecular signatures for diagnosis and therapies of glioblastoma by combining supervised and unsupervised learning approaches.Scientific reports · 2024Article
- Targeted Glioma Therapy-Clinical Trials and Future Directions.Pharmaceutics · 2024Review
- Posterity of nanoscience as lipid nanosystems for Alzheimer's disease regression.Materials today. Bio · 2023Review
- Quercetin and Its Nano-Formulations for Brain Tumor Therapy-Current Developments and Future Perspectives for Paediatric Studies.Pharmaceutics · 2023Review
- Review
- Neuro-nanotechnology: diagnostic and therapeutic nano-based strategies in applied neuroscience.Biomedical engineering online · 2023Review
- Emodin coupled with high LET neutron beam-a novel approach to treat on glioblastoma.Journal of radiation research · 2022Article
- Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy.International journal of molecular sciences · 2022Review
- Theranostic Potential of Adaptive Cold Atmospheric Plasma with Temozolomide to Checkmate Glioblastoma: An In Vitro Study.Cancers · 2022Article
- Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: advance and prospect.Journal of nanobiotechnology · 2022Review
- TRP Family Genes Are Differently Expressed and Correlated with Immune Response in Glioma.Brain sciences · 2022Article
- Editorial: Brain Cancers: New Perspectives and Therapies.Frontiers in neuroscience · 2022Article
- Matteucinol combined with temozolomide inhibits glioblastoma proliferation, invasion, and progression: an in vitro, in silico, and in vivo study.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2022Article
- Lipid nanostructures for targeting brain cancer.Heliyon · 2021Review
- Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2021Article
- Pharmacological Modulation of Blood-Brain Barrier Permeability by Kinin Analogs in Normal and Pathologic Conditions.Pharmaceuticals (Basel, Switzerland) · 2020Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundMalignant brain tumors are among the most challenging to treat and at present there are no uniformly successful treatment strategies. Standard treatment regimens consist of maximal surgical resection followed by radiotherapy and chemotherapy. The limited survival advantage attributed to chemotherapy is partially due to low CNS penetration of antineoplastic agents across the blood-brain barrier (BBB).
objectiveThe objective of this paper is to review recent approaches to delivering anticancer drugs into primary brain tumors.
methodsBoth preclinical and clinical strategies to circumvent the BBB are considered that include chemical modification and colloidal carriers.
conclusionAnalysis of the available data indicates that new approaches may be useful for CNS delivery, yet an appreciation of pharmacokinetic issues and improved knowledge of tumor biology will be needed to affect significantly drug delivery to the target site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.